Following a legal challenge to the process used to produce NICE's existing guidance on prevention of osteoporotic fractures, the original recommendations remain unchanged in the updated guidance documents published last friday. This means that postmenopausal women with osteoporosis at risk of fractures will continue to have access to a range of drugs to help either prevent them suffering a first fracture (primary prevention) or prevent further fractures after they have suffered one (secondary prevention)...
More...
More...